Marco Stringhini
Principal Investigator, Project Leader Almirall
Marco Stringhini is a Principal Investigator and Project Leader at Almirall, where he leads drug discovery projects and has progressed through increasingly senior scientific roles since joining the company in 2023.
Prior to Almirall, Marco conducted postdoctoral research in Experimental Immunology at the University of Basel, following a PhD at ETH Zurich in Tumor Immunotherapy. His background combines extensive academic research experience with project leadership in the pharmaceutical industry, and his expertise spans immunology, and early-stage drug discovery, including antibody discovery, protein engineering, mRNA-therapeutics, and cell therapies.
Seminars
Friday 19th February 2027
Panel Discussion: Defining the Most Valuable Use Cases for mRNA-LNP Therapeutics: Prioritising Applications with the Greatest Clinical & Commercial Potential
4:00 pm
- Identifying “sweet spots” for mRNA-LNP therapeutics based on dosing frequency, administration route & immune considerations
- Focusing development on validated applications: Cancer vaccines, infectious disease vaccines, protein replacement & in vivo CAR-T
- Learning from clinical setbacks to understand biological & commercial limitations of the platform
